Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23058IDB-L5

Select Item

Empower your strategies with our Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024 report and make more profitable business decisions.

Methicillin-resistant Staphylococcus aureus (MRSA) infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections; others are hospital-aquired (HA-MRSA). Risk factors for MRSA infection are hemodialysis, weakened immune system, admission to hospitals, and wounds. Symptoms include skin rashes, fatigue, chest pain, fever, and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
Key Targets
· Bacterial Cell Membrane; Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI; Bacterial Cell Wall; Peptidoglycan; 23S Ribosomal RNA; DNA Gyrase; DNA; DNA Topoisomerase IV; Lipid II Flippase MurJ; and Staphylococcus aureus Alpha Hemolysin
Key Mechanisms of Action
· Bacterial Cell Membrane Disruptor; Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor; Bacterial Cell Wall Disruptor; Peptidoglycan Inhibitor; 23S Ribosomal RNA Inhibitor; DNA Gyrase Inhibitor; DNA Inhibitor; DNA Topoisomerase IV Inhibitor; Lipid II Flippase MurJ Inhibitor; and Lipid II Inhibitor
Key Routes of Administration
· Oral; Intravenous; Topical; Nasal; Inhalational; Parenteral; Ophthalmic; Cutaneous; Intramuscular; and Transdermal
Key Molecule Types
· Small Molecule; Synthetic Peptide; Subunit Vaccine; Monoclonal Antibody; Recombinant Protein; Recombinant Enzyme; Biologic; Vaccine; Toxoid Vaccine; and Fusion Protein
Major Companies
· Acticule Life Sciences Ltd; Cellics Therapeutics Inc; Curza Global LLC; Helperby Therapeutics Group Ltd; Hsiri Therapeutics LLC; NovoBiotic Pharmaceuticals LLC; MicuRx Pharmaceuticals Inc; LegoChem Biosciences Inc; Wayne State University; and University of Nebraska Medical Center

Scope

  • Therapeutics in Development: Covering 173 molecules, with 115 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

AbbVie Inc
AbVacc Inc
Acticule Life Sciences Ltd
Acurx Pharmaceuticals Inc
AEON Medix Inc
AimMax Therapeutics Inc
AlphaMab Co Ltd
Amicrobe Inc
Amprologix Ltd
Andira Pharmaceuticals
AnyGen Co Ltd
Aphios Corp
Aridis Pharmaceuticals Inc
Arietis Corp
Arizona State University
Aurigene Oncology Ltd
aVaxziPen Limited
Basilea Pharmaceutica Ltd
Bharat Biotech Ltd
Biocidium Biopharmaceuticals Inc
Biological Mimetics Inc
Biomendics LLC
BioPlx Microbiomics Pvt Ltd
Bioseka UAB
Bioversys AG
Botanix Pharmaceuticals Ltd
Cantab Anti-infectives Ltd
Catholic University of Korea
Cellics Therapeutics Inc
Centivax Inc
Chengdu Olymvax Biopharmaceuticals Inc
China Agricultural University
Chinese Academy of Medical Sciences and Peking Union Medical College
Crestone Inc
CrystalGenomics Inc
Curza Global LLC
Daiichi Sankyo Co Ltd
Debiopharm International SA
DeNovaMed Inc
Destiny Pharma Plc
Eagle Pharmaceuticals Inc
East China University Of Science And Technology
ESA Patentverwertungsagentur Sachsen-Anhalt GmbH
Evoq Nano Inc
Exbaq LLC
Georgia State University
Global BioLife Inc Ltd
H. Lee Moffitt Cancer Center & Research Institute Inc
Harvard Medical School
Harvard University
Helmholtz Centre for Infection Research
Helperby Therapeutics Group Ltd
Hsiri Therapeutics LLC
HyPharm GmbH
ImmunArtes LLC
Immupharma Plc
Inimmune Corp
Integrated BioTherapeutics Inc
ioGenetics Inc
Jawaharlal Nehru Centre for Advanced Scientific Research
Jilin University
Johns Hopkins University
Johnson & Johnson
KBP Biosciences Co Ltd
Lakewood-Amedex Inc
Lead Discovery Center GmbH
LegoChem Biosciences Inc
Lysimmune BioScience
Lyticon LLC
Madam Therapeutics BV
Matrisys Bioscience Inc
Meiji Seika Pharma Co Ltd
MGB Biopharma Ltd
Microbiotix Inc
MicuRx Pharmaceuticals Inc
Nanyang Technological University
National Taiwan University
NES Biotechnology Co Ltd
Northeastern University
Novalex Therapeutics Inc
NovoBiotic Pharmaceuticals LLC
NYU Robert I. Grossman School of Medicine
Olgram SAS
Opal Biosciences Ltd
Oppilotech Ltd
Oragenics Inc
Oryn Therapeutics
Oxford Drug Design Ltd
Palacky University Olomouc
Paris Descartes University
Peptineo
Phico Therapeutics Ltd
Prokaryotics Inc
Prommune Inc
Purdue University
Pusan National University
Q2 Pharma Ltd
Quratis Inc
QureTech Bio AB
R-Pharm
Recce Pharmaceuticals Ltd
Rice University
Rockefeller University
Sano Chemicals Inc
Scandion Oncology AS
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai High-Tech Bioengineering Co Ltd
Shanghai MengKe Pharmaceuticals Inc
Shanghai Shangyao Xinya Pharmaceutical Co Ltd
Shanghai Space Peptides Pharmaceutical Co Ltd
smartbax GmbH
Sorrento Therapeutics Inc
Stony Brook University
Swansea University
TaeJoon Pharmaceuticals Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
TAXIS Pharmaceuticals Inc
Technical University of Munich
Telum Therapeutics SL
TGV-Inhalonix Inc
The Lundquist Institute
The University of British Columbia
Theralia AB
Therapeutic Systems Research Laboratories Inc
Trellis Bioscience LLC
University of California Los Angeles
University of California San Diego
University of Illinois
University of Lincoln
University of Miami
University of Nebraska Medical Center
University of North Texas Health Science Center
University of Notre Dame
University of Oklahoma
University of Pittsburgh
University of Queensland
University of South Florida
University of Southern Denmark
University of Strasbourg
University of Tennessee Research Foundation
University of Wisconsin Madison
University of Wisconsin-La Crosse
Vanderbilt University
Venomyx Inc
Viosera Therapeutics
Virginia Polytechnic Institute and State University
Vitas Pharma Research Pvt Ltd
VLP Biotech Inc
Wayne State University
Wockhardt Ltd
Wuhan University
Yale University
Yungjin Pharm Co Ltd
Zhuhai Trinomab Biotechnology Co Ltd
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Methicillin-Resistant Staphylococcus aureus (MRSA) Infections reports
Pharmaceuticals
New
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024 in real time.

  • Access a live Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more